Impact of radiation dose and standardized uptake value of (18)FDG PET on nodal control in locally advanced cervical cancer.

Abstract

BACKGROUND:

Despite local control now exceeding 90% with image-guided adaptive brachytherapy (IGABT), regional and distant metastases continue to curb survival in locally advanced cervical cancer. As regional lymph nodes often represent first site of metastatic spread, improved nodal control could improve survival. The aim of this study was to examine optimal volume and dose of external beam radiotherapy (EBRT) to maximize regional control including dose contribution from IGABT.

MATERIAL AND METHODS:

In total 139 patients from the EMBRACE study were analyzed. Individual nodal dose was determined by dose-maps from EBRT and IGABT. All PET/CT scans were re-evaluated and nodal maximal standard uptake value (SUVmax) was determined. Nodal failures were registered to planning scans and related to boosted nodes and treated volume. Relation between SUVmax and nodal control as well as the pattern of regional nodal failure were analyzed.

RESULTS:

Eighty-four patients were node positive. Nine patients had all metastatic nodes surgically removed. Seventy-five patients had 209 nodes boosted with EBRT. Median nodal boost dose was 62 Gy EQD2 (53-69 Gy EQD2). Median SUVmax was 6 (2-22). No patients had persistent nodal disease, but six patients recurred in a boosted node. SUVmax was significantly higher in nodes that recurred (p = 0.02). However, there was no correlation to nodal dose or volume. Twenty-one patients had a nodal failure including para-aortic nodal (PAN) metastases above the irradiated volume. Nine patients had a PAN-only failure. Patients receiving ≤ 4 cycles of weekly cisplatin had higher risk of nodal failure (p < 0.01).

CONCLUSION:

Current RT practice provides a high level of control in both boosted nodes and the elective irradiated regional target. However, a high nodal SUVmax is a negative prognostic predictor for nodal control. Attention should be raised to administration of a complete schedule of concurrent chemotherapy as well as treatment of para-aortic nodes.

• Authors: Anne Ramlov, Petra S Kroon, Ina M Jürgenliemk-Schulz, Astrid A C De Leeuw, Lars Christian Gormsen, Lars Ulrik Fokdal, Kari Tanderup, Jacob Christian Lindegaard
• Journal: Acta oncologica (Stockholm, Sweden) (Acta Oncol) Vol. 54 Issue 9 Pg. 1567-73 ( 2015) ISSN: 1651-226X [Electronic] England
• PMID: 26271799 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Radiopharmaceuticals
• Fluorodeoxyglucose F18
• Cisplatin

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Aorta
• Brachytherapy
• Carcinoma, Squamous Cell (secondary, therapy)
• Cisplatin (therapeutic use)
• Female
• Fluorodeoxyglucose F18
• Follow-Up Studies
• Humans
• Lymph Nodes (diagnostic imaging, radiation effects, surgery)
• Lymphatic Metastasis
• Magnetic Resonance Imaging
• Middle Aged
• Neoplasm Recurrence, Local (diagnosis)
• Pelvis
• Positron-Emission Tomography
• Radiopharmaceuticals
• Radiotherapy Dosage
• Radiotherapy, Intensity-Modulated
• Tomography, X-Ray Computed
• Treatment Failure
• Uterine Cervical Neoplasms (pathology, therapy)
• Young Adult